Skip to content
Screener

Tango Therapeutics TNGX Q1 2025 earnings

Reported May 12, 2025 · Before market open

Revenue$5.4MMiss by $967.3K
EPS-$0.36Miss by $0.02
Revenue estimate$6.4M
EPS estimate-$0.34

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$0.34

Financials

Q1 2025

Income statement

See full
Revenue$5.4M-16.7%
Operating income-$42.5M-0.7%
Net income-$39.9M-5.2%
EPS (diluted)-$0.36-2.9%

Balance sheet

See full
Cash & equivalents$61.0M-4.3%
Total debt$36.9M-3.4%
Total equity$166.8M-36.9%
Total assets$274.3M-32.5%

Cash flow

See full
Operating cash flow-$41.7M-10.1%
CapEx$51.0K-73.8%
Free cash flow-$41.7M-9.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$148.11M-80.8%
Enterprise value$124.05M-83.4%
P/S3.6×-17.1×

Profitability

See full
Operating margin-355.9%+18.9pp
Net margin-322.7%+26.5pp
FCF margin-331.7%+4.0pp

Returns & leverage

See full
Return on equity-61.3%+33.2pp
Debt / equity0.2×+0.1×
Current ratio6.3×-2.0×

FAQ

When did Tango Therapeutics report Q1 2025 earnings?
Tango Therapeutics (TNGX) reported Q1 2025 earnings on May 12, 2025 before market open.
What were Tango Therapeutics's Q1 2025 revenue and EPS?
Tango Therapeutics reported revenue of $5.4M and eps of $-0.36 for Q1 2025.
Did Tango Therapeutics beat estimates in Q1 2025?
Revenue missed the consensus estimate of $6.4M by $967.3K. EPS missed the consensus estimate of $-0.34 by $0.02.
How did Tango Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 16.7% from $6.5M a year earlier and eps declined 2.9% from $-0.35.
Where can I find Tango Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-068546) and the 10-Q periodic report (0000950170-25-068549) directly on SEC EDGAR. The filing index links above go to sec.gov.